The complexities of the pathology-pathogenesis relationship in Alzheimer disease.

Current pathogenic theories for Alzheimer disease (AD) and aging favor the notion that lesions and their constituent proteins are the initiators of disease due to toxicity. Whether this is because structural pathology is traditionally viewed as deleterious, and whether this, in turn, is a fundamental misinterpretation of the relationship between pathology and pathogenesis across the spectrum of chronic diseases, remains to be determined. As more and more detailed information about the biochemical constituents of AD lesions becomes available, it may also be argued that just as much knowledge of cellular physiology as pathophysiology has been gained. Indeed, essentially all major proteins in AD lesions are derived from molecular cascades, which are in turn highly conserved across cells, tissues, and species. Moreover, the lesions themselves are observed in the cognitively intact, and sometimes in large numbers, while major consensus criteria indicate that an extent of pathology is normal with advanced age. As the medical science community continues to pursue lesion targeting for therapeutic purposes, the notion that AD pathology is indicative of an active host response or environmental adaptation, and therefore a poor target, is becoming clearer.

[1]  C. Haass,et al.  Trafficking and proteolytic processing of APP. , 2012, Cold Spring Harbor perspectives in medicine.

[2]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[3]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[4]  P. S. St George-Hyslop,et al.  Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. , 1987, Science.

[5]  Bengt Winblad,et al.  Defective brain microtubule assembly in Alzheimer??s disease , 1987 .

[6]  Brian J Bacskai,et al.  Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Selkoe,et al.  Effects of the amyloid precursor protein Glu693-->Gln 'Dutch' mutation on the production and stability of amyloid beta-protein. , 1999, The Biochemical journal.

[8]  P. Schofield,et al.  Alzheimer's disease with spastic paraparesis and 'cotton wool' plaques: two pedigrees with PS-1 exon 9 deletions. , 2003, Brain : a journal of neurology.

[9]  S ORAM,et al.  STAPHYLOCOCCI RESISTANT TO NEOMYCIN AND BACITRACIN. , 1965, Lancet.

[10]  Colin L Masters,et al.  Crystal Structure of the Amyloid-β p3 Fragment Provides a Model for Oligomer Formation in Alzheimer's Disease , 2011, The Journal of Neuroscience.

[11]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[12]  K. Grzeschik,et al.  The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor , 1987 .

[13]  M. Kidd Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease , 1963, Nature.

[14]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[15]  M. Graeber,et al.  Reanalysis of the first case of Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[16]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[17]  C. Brayne,et al.  Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. , 2009, Journal of Alzheimer's disease : JAD.

[18]  M. Mendez,et al.  Frontotemporal Dementia-like Phenotypes Associated With Presenilin-1 Mutations , 2006, American journal of Alzheimer's disease and other dementias.

[19]  R. Castellani,et al.  Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. , 2012, Archives of medical research.

[20]  J. Price,et al.  Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.

[21]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[22]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[23]  Bradley T. Hyman,et al.  Tau pathophysiology in neurodegeneration: a tangled issue , 2009, Trends in Neurosciences.

[24]  M. Wolfe Tau Mutations in Neurodegenerative Diseases* , 2009, Journal of Biological Chemistry.

[25]  K. Jellinger,et al.  Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature , 2012, Journal of neuropathology and experimental neurology.

[26]  W. Pardridge,et al.  Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. , 2000, Bioconjugate chemistry.

[27]  Z. Khachaturian Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[28]  K. Blennow,et al.  Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[29]  H. Möller,et al.  The case described by Alois Alzheimer in 1911 , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[30]  M. Doran,et al.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.

[31]  R. Castellani,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[32]  S. Younkin Evidence that Aβ42 is the real culprit in alzheimer's disease , 1995 .

[33]  Shankar Vallabhajosula,et al.  Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid. , 2011, Seminars in nuclear medicine.

[34]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[35]  F. Tarazi,et al.  Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive? , 2013, Expert opinion on biological therapy.

[36]  P. S. St George-Hyslop,et al.  Familial Dementia With Frontotemporal Features Associated With M146V Presenilin‐1 Mutation , 2013, Brain pathology.

[37]  R. Castellani,et al.  Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’ , 2011, The Journal of pathology.

[38]  M. Graeber,et al.  A presenilin 1 mutation in the first case of Alzheimer's disease , 2013, The Lancet Neurology.

[39]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[40]  S. Younkin Evidence that A beta 42 is the real culprit in Alzheimer's disease. , 1995, Annals of neurology.

[41]  Peter R Schofield,et al.  The Genetics of Dementia , 2013 .

[42]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[43]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[45]  Nick C Fox,et al.  Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.

[46]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[47]  H. Braak,et al.  Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship , 2009, Journal of neuropathology and experimental neurology.